-
Junshi Launches Head-to-Head Phase III Clinical Trial of New Crown Oral Drug VV116 Compared with Pfizer's Paxlovid
Time of Update: 2022-05-18
On April 19, the website of the China Clinical Trials Registry announced a multi-center, single-blind, randomized, controlled clinical study of Junshi Bio/Wangshan Wangshui VV116 head-to-head versus Pfizer Paxlovid in the early treatment of mild to severe new coronary pneumonia .
-
Hengrui Medicine irinotecan hydrochloride liposome injection for the treatment of advanced pancreatic cancer
Time of Update: 2022-05-18
Article source: Medical Cube InfoOn April 20, Hengrui announced that it had submitted a marketing application for irinotecan hydrochloride liposome injection to the Food and Drug Administration, in combination with 5-FU/LV second-line treatment of locally advanced or metastatic pancreatic cancer after failure of gemcitabine therapy .
-
In 2022, the centralized procurement of proprietary Chinese medicines will start in an all-round way!
Time of Update: 2022-05-18
For example, on April 18, the Tibet Autonomous Region Medical Insurance Bureau issued the "Notice on Carrying out the Work Related to the Procurement of Selected Varieties by the Inter-Provincial Alliance of Chinese Patent Medicines", which pointed out that the implementation time for the centralized purchase of Chinese Patent Medicine Alliance in Hubei and other 19 provinces in Tibet Autonomous Region will be 2022.
-
The demand for expansion of biological product production lines has increased sharply, and pharmaceutical machine companies have increased R&D and actively deployed production capacity
Time of Update: 2022-05-18
Pharmaceutical equipment (Source: Pharmaceutical Network) Taking the representative domestic pharmaceutical equipment companies such as Chutian Technology, Tofflon, and Canaan Technology as examples, the public financial report data shows that in the first three quarters of 2020 and 2021 , Chutian Technology achieved revenue of 3.
-
In the first quarter of 2022, the output of traditional Chinese medicinal materials in Guizhou, the four major medicinal material producing areas in China, increased by 60.0%
Time of Update: 2022-05-18
The reporter learned from the press conference on the main statistical data of Guizhou Province for the first quarter of 2022 held by the Information Office of the People's Government of Guizhou Province on the 20th that in the first quarter of 2022, the production of Guizhou's planting industry remained stable, and the output of Chinese medicinal materials increased by 60.
-
Announcement of latest persistence and booster data for Clover's new coronary pneumonia adjuvanted protein vaccine
Time of Update: 2022-05-18
A new dataset from an extended follow-up analysis confirms earlier findings and shows high and durable protection in individuals approximately 6 months after basal immunization with SCB-2019 (CpG 1018/aluminum adjuvant) .
-
The first TCR-T product for the treatment of liver cancer was approved for clinical use
Time of Update: 2022-05-18
At present, Xiangxue Life Sciences has completed the preclinical research work on the new TCR-T drug TAES1901 in China for hepatocellular carcinoma whose genotype is HLA-A*02:01 and the tumor antigen AFP expression is positive .
-
The 9th domestic Yuheng Pharmaceutical LAG3 monoclonal antibody was approved for clinical use
Time of Update: 2022-05-18
Article source: Medical Cube InfoAuthor: sunshineOn April 19, the CDE official website showed that Yuheng Pharmaceutical's recombinant fully human anti-LAG-3 monoclonal antibody injection was approved for clinical use in the treatment of advanced malignant tumors .
-
The National Medical Insurance Administration notified the special flight inspection of Wuhan Tongji Hospital
Time of Update: 2022-05-18
In March 2022, based on the reported clues, the National Medical Insurance Bureau, together with the National Health Commission and the State Administration for Market Regulation, conducted an unannounced inspection of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (referred to as "Tongji Hospital") to guide Hubei Provincial Medical Insurance Bureau, Wuhan The Municipal Medical Insurance Bureau will verify and deal with the relevant issues .
-
The development process of domestic improved new drugs is accelerating, and the number of applications is continuing to grow
Time of Update: 2022-05-18
In fact, in recent years, with the improvement of the research and development capabilities of domestic pharmaceutical companies, some high-barrier technologies, such as liposomes, microspheres, oral dissolving membranes, micelles, transdermal patches, etc.
-
The $100 billion rare disease drug market is "attractive", and pharmaceutical companies have stepped up to enter the "enclosure"
Time of Update: 2022-05-17
5 billion to enter the field of rare diseases, and announced the acquisition 3 months later Chord Therapeutics, a drug research and development company focusing on rare neuroinflammatory diseases, has further strengthened its layout in the field of rare diseases .
-
Lingke Pharma LNK01004 was approved for clinical use in the treatment of psoriasis in China
Time of Update: 2022-05-17
LNK01004 can simultaneously inhibit multiple inflammatory cytokines and disease-inducing signaling pathways associated with psoriasis, and has the potential for optimal efficacy .
LNK01004 showed good efficacy and safety in animal experiments .
-
The "Thousand County Project" county hospital is here!
Time of Update: 2022-05-17
On April 20, the General Office of the National Health and Health Commission issued the "Notice on Printing and Distributing the List of County Hospitals in the "Thousand-County Project" County Hospi
-
In 2022, the "close relatives" of Class 1 innovative drugs will accelerate the launch of the outbreak
Time of Update: 2022-05-17
From the perspective of new improved chemical drugs (excluding new indications) approved from 2020 to the present, there are a total of levoornidazole tablets from Shenghe Pharmaceuticals, olanzapine oral dissolving film from Hansoh, and montelukast from Qilu Pharmaceuticals.
-
Sinopharm Yixin Cytarabine for Injection to be included in priority review
Time of Update: 2022-05-17
It is also a functional general-purpose cancer treatment drug, such as cytarabine combined with anthracyclines for the treatment of acute myeloid leukemia and lymphoma, etc.
-
Recombinant humanized anti-HER2-ADC for injection approved by Zhejiang Pharmaceutical Subsidiary
Time of Update: 2022-05-17
In 2019, the company launched a phase I clinical study of ARX788 in the treatment of patients with HER2-positive advanced metastatic gastric cancer and gastroesophageal junction adenocarcinoma.
-
In the first quarter, the production and sales growth of the pharmaceutical industry was gratifying, and the total output value increased by more than 50%
Time of Update: 2022-05-17
27% year-on-year to 385 million yuan, and the net profit attributable to shareholders of the listed company increased by 0.
16% year-on-year to 550 million yuan; the net profit before and after non-deduction attributable to shareholders of listed companies in the same period increased by 135.
-
News of executives of pharmaceutical companies in April: personnel changes in 3 multinational pharmaceutical companies!
Time of Update: 2022-05-17
Among them, Zhang Ying, president of Novartis Pharmaceuticals (China), was appointed as president and managing director of innovative drugs China.
According to the data, Tara Frenkl once served as senior vice president and head of oncology drug development at GlaxoSmithKline.
-
The AI pharmaceutical track is advancing by leaps and bounds, with more than 10 new financings in the first quarter of 2022
Time of Update: 2022-05-16
On March 31, the company announced the completion of a Pre A+ round of financing of more than 100 million yuan, led by Jianyi Capital (formerly Sinopharm Capital), and continued to be supported by funds such as old shareholders Honghui Fund, Bopu Capital and Shanxing Capital .
-
Cordyceps sinensis on the Qinghai-Tibet Plateau enters the mining season of traditional "soft gold" or welcomes a new trend
Time of Update: 2022-05-16
Picking in the mountains: "soft gold" can be called a magic weapon to increase income At present, in the relatively low Caoshan Mountain with an altitude of about 3,000 meters, the excavation of Cordyceps sinensis has begun, and for the Cordyceps sinensis in the area of more than 5,000 meters above sea level, the business has issued an announcement to accept pre-excavation reservations .
